Raptor is a NASDAQ-listed biopharmaceutical company with the mission to develop and commercialize life-altering therapeutics that treat debilitating and often fatal diseases.
Raptor's lead product, PROCYSBI® (cysteamine bitartrate) delayed release capsules, received FDA approval on April 30, 2013. The European equivalent, PROCYSBI® gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), received European Commission approval in September 2013.
Raptor’s product pipeline may advance therapeutic options for additional indications. Raptor's management team consists of repeat entrepreneurs with the experience to build a successful company.
Raptor owns or has exclusive licenses to protect its product candidates and drug-targeting platforms. To date, Raptor's patent portfolio includes patents relating to its delayed release cysteamine bitartrate and NeuroTrans™ technologies and patent applications covering cysteamine, Convivia™, NeuroTrans™ and HepTide™. Raptor also holds exclusive licenses covering RP103 for nephropathic cystinosis (PROCYSBI™), RP103 for NASH, cysteamine and related compounds for Huntington's disease and tissue fibrosis, Rett syndrome, cysteamine analogues for Parkinson's disease, and artimisinin and cysteamine for malaria. Raptor periodically updates information on its Intellectual Property through Company press releases. Additional information can be obtained through the USPTO web site (www.uspto.gov).